ValiRx plc (GB:VAL) has released an update.
ValiRx Plc, a life science company dedicated to developing early-stage cancer therapeutics and women’s health solutions, has announced the immediate resignation of Kevin Cox as Chairman and Director. The company, which has been listed on the AIM Market of the London Stock Exchange since October 2006, is known for its innovative approach to streamlining drug development processes and bringing novel drug candidates to clinical development and commercialization.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
